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Abstract
We conducted a two-stage genome-wide association study to identify common genetic variation altering risk of the
metabolic syndrome and related phenotypes in Indian Asian men, who have a high prevalence of these conditions. In Stage
1, approximately 317,000 single nucleotide polymorphisms were genotyped in 2700 individuals, from which 1500 SNPs
were selected to be genotyped in a further 2300 individuals. Selection for inclusion in Stage 1 was based on four metabolic
syndrome component traits: HDL-cholesterol, plasma glucose and Type 2 diabetes, abdominal obesity measured by waist to
hip ratio, and diastolic blood pressure. Association was tested with these four traits and a composite metabolic syndrome
phenotype. Four SNPs reaching significance level p,561027 and with posterior probability of association .0.8 were found
in genes CETP and LPL, associated with HDL-cholesterol. These associations have already been reported in Indian Asians and
in Europeans. Five additional loci harboured SNPs significant at p,1026 and posterior probability .0.5 for HDL-cholesterol,
type 2 diabetes or diastolic blood pressure. Our results suggest that the primary genetic determinants of metabolic
syndrome are the same in Indian Asians as in other populations, despite the higher prevalence. Further, we found little
evidence of a common genetic basis for metabolic syndrome traits in our sample of Indian Asian men.
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Introduction
The metabolic syndrome is the combination of most or all of:
raised plasma glucose, abdominal obesity, dyslipidemia, and high
blood pressure [1]. People affected by the metabolic syndrome are
at an increased risk of coronary heart disease and type 2 diabetes
(T2D), which are large and rapidly-increasing causes of illness and
death globally. Indian Asians have a high prevalence of the
metabolic syndrome compared with Europeans, and metabolic
syndrome traits are highly heritable in Indian Asians (h2 between
0.27and 0.53 [2]). It is thought that the syndrome results from a
complex interplay of genetic and environmental factors, and
genetic variants underlying metabolic traits have been identified at
several loci in European-origin populations. Little is known about
whether the same genetic mechanisms trigger metabolic distur-
bances in Indian Asians as in Europeans, nor whether there are
genetic mechanisms that are common across metabolic syndrome
traits in Indian Asians. Our study was intended to investigate these
two questions.
We screened common SNPs for association with metabolic
syndrome and four of its component traits in a sample of Indian
Asian men. Metabolic syndrome traits vary substantially between
men and women; to reduce heterogeneity we included only men in
this study. The four traits included three quantitative traits
(diastolic blood pressure DBP, waist-hip ratio WHR, and HDL
cholesterol), and one binary (presence or absence of T2D). We also
tested a metabolic syndrome phenotype that was created from
individual metabolic traits. We used a two-stage design, with
independent ‘‘top and tail’’ sample selection and different
genotyping platforms in each stage. Overall, about 1500 SNPs,
primarily selected from the Stage 1 results, were genotyped in
approximately 5000 individuals in the two stages combined. We
report p-values of association under an additive model, after
adjustment for covariates (see Materials and Methods). Although
familiar, p-values suffer from problems of interpretation and the
difficulty of combining signals under different genetic models [3].
We therefore also report the posterior probability of association
(PPA) for a 4:1 weighting of additive and general genetic models
(see Materials and Methods). We assumed a prior probability of
association of 1024 for each trait, which corresponds to a cautious
assumption that only around 300 kb of the genome is in high
linkage disequilibrium (LD) with a causal variant. The PPA is a
directly interpretable measure of weight of evidence for associa-
tion, and gives due emphasis to additive genetic models while also
allowing strong, non-additive signals of association to be taken into
account.
Results
Characteristics of individuals selected for genotyping in each
stage are shown in Table 1. Quantile-quantile (Q-Q) and signal
intensity plots for Stage 1 results are in Figure S1. In summary,
after combining data from stages 1 and 2 (Figure 1), four SNPs at
two loci were strongly associated with HDL-cholesterol
(p,561027, PPA.0.8). In addition, a TCF7L2 SNP had a PPA
of almost 0.7 for T2D (p= 761027). A further four SNPs were
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associated with HDL or DBP at p,1026 and PPA.0.5. These
results are further described below and in Table 2, and a list of all
SNPs significant at p,1025 from the combined analysis is in
Table S1.
Two SNPs in the FTO gene, which has a well-established
association with obesity (e.g. [4]), were genotyped in our study
(rs8050136 and rs3751812), and showed only weak association
with WHR (p=4.661023 and 4.461023). No SNP showed strong
association with the compound metabolic syndrome phenotype.
The largest PPA for a SNP associated with the metabolic
syndrome as defined by the IDF [1] was 0.08 (p = 6.861026) at
rs12957347, about 180 kb upstream from gene PMAIP1 (phorbol-
12-myristate-13-acetate-induced protein) for which no associations
have previously been reported [5], and 288 kb downstream from
MC4R (Melanocortin 4 Receptor). Rs12957347 is correlated with
rs12970134 reported in [6] (r2 = 0.7) which is 155 kb downstream
of MC4R, and gave a p-value = 2.461025 in the current study,
and therefore is not included in Table 2.
Detail of association results for each trait
HDL-cholesterol. Associations with p,1026 and PPA.0.5
were found at two SNPs near CETP, two SNPs at 8p21.3 near the
LPL (Lipoprotein lipase) gene, two SNPs at 11q12.2 near the
FADS1 and FADS2 (Fatty acid desaturase) genes, and one SNP at
21q22.3 near FLJ41733. These associations have been reported
elsewhere in Indian Asians and Europeans [6,7], with the
exception of FADS1 and FADS2, which have been reported in
Europeans [7,8], but not previously in Indian Asians. The minor
allele fractions (MAF) and effect sizes among the Indian Asians in
our study are similar to those previously reported in other
populations (see references listed in Table 2). The association at
21q22.3 near FLJ41733 has not previously been reported, nor is
this locus known to have any metabolic function. A further SNP
showed modest association (p,1026, PPA=0.35) at C11orf10,
which maps to 11q12.2 near FADS1/FADS2. An LD table for the
HDL-associated SNPs in the above three loci is in Table S2.
Type 2 diabetes. SNP rs7903146 near TCF7L2 (p,1026 and
PPA=0.69) is a well-established T2D SNP in Caucasians [9–15].
The MAF and effect size among the Indian Asians in our study are
similar to those previously reported for Europeans (Table 2).
Diastolic blood pressure. SNP rs7865146 is located,3 kb
from the Endoglin (ENG) gene. In our study it showed suggestive
evidence of association (PPA=0.57), each copy of the rare allele
reducing DBP by 1.19 mmHg (95% CI: 0.71 to 1.67). An
association with DBP is biologically plausible: ENG encodes a type
I membrane glycoprotein and is part of the TGF-beta receptor
complex. It is crucial for maintaining vascular integrity and has a
role in the development of the cardiovascular system [16]. Its
expression is regulated during heart development [5]. A large meta
analysis did not show association with variants within or near
ENG in Europeans [17]. Although that study included 12,000
Indian Asians, only 12 SNPs were genotyped in these individuals,
none of them near ENG.
Discussion
The metabolic syndrome and its components are a major health
concern, particularly in Indian Asians. The GWAS approach has
met with some success in dyslipidemia, type 2 diabetes and obesity
phenotypes [4,7,15,17], with most studies to date being conducted
in Europeans. Our study has further confirmed a number of
previously reported associations, in some cases for the first time in
Indian Asians, and identified some novel suggestive associations
requiring further confirmation.
The metabolic syndrome consists of a number of phenotypes
that tend to co-occur, raising the question of whether or not they
have common genetic mechanisms [18,19]. A number of
definitions for the metabolic syndrome have been developed over
the years, including those proposed by IDF, NCEP ATPIII or
WHO [1,20,21]. We chose the IDF definition, which is the most
recent and incorporates ethnicity by providing different criteria for
the metabolic syndrome in different ethnic groups [1]. Most
published associations for the metabolic syndrome are only with
individual component phenotypes, or in some cases with multiple
phenotypes but not matching any of the above definitions. Joy
et al. [22] reviewed a large number of genetic association and
linkage studies for the metabolic syndrome using all definitions,
and concluded that these studies have not provided any confirmed
associations. Our results for Indian Asians also found no evidence
for common genetic mechanisms underlying the metabolic
syndrome, despite its high prevalence in this population, and the
Table 1. Characteristics of genotyped Indian Asian men.
Stage 1 (N=2684) Stage 2 (N=2020) Combined (N=4560)
Description
Mean (SD) or
prevalence Range
Mean (SD) or
prevalence Range
Mean (SD) or
prevalence Range
Age (yrs) 50.0 (11.0) 35.0–74.8 47.5 (10.7) 35.0–74.8 49.9 (10.9) 35.0–74.8
CHD (%) 8% - 8% - 8% -
Hypertension (%) 33% - 33% - 33% -
T2D (%) 25% - 25% - 25% -
Cholesterol med (%) 18% - 17% - 18% -
SBP (mmHg) 134.2(20.6) 87–231 133.8 (19.9) 89–244 134.1 (20.4) 87–244
DBP (mmHg) 82.6 (12.1) 53–132 83.0 (11.9) 55–149 82.8 (12.0) 53–149
WHR 0.97 (0.07) 0.55–1.29 0.97 (0.07) 0.68–1.41 0.97(0.07) 0.55–1.41
HDL-cholesterol (mmol/l) 1.22 (0.31) 0.57–3.28 1.22 (0.33) 0.25–4.85 1.22(0.32) 0.25–4.85
Glucose (mmol/l) 6.03 (2.18) 2.60–21.90 6.04(2.20) 2.00–21.40 6.04(2.19) 2.00–21.9
Metabolic syndrome (IDF) 47.0% - 49.0% - 48.0% -
Prevalence of the metabolic syndrome is for the selected sample and is not representative of the general population.
doi:10.1371/journal.pone.0011961.t001
Metabolic Syndrome GWAS
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Figure 1. Genome-wide association results of the combined Stage 1 and Stage 2 analysis.
doi:10.1371/journal.pone.0011961.g001
Metabolic Syndrome GWAS
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fact that we enriched for extreme metabolic syndrome phenotypes
through selective genotyping of the participants.
Bayesian statistical methods are still rarely used in reporting
genetic association studies, and we hope that our report will give
further illustration of their potential benefits. Firstly, intuition gives
little guide as to how important is an association of, say 861027,
because the answer depends on power which in turn depends on
several factors including the MAF. In contrast, a PPA of 0.6 is
immediately interpretable irrespective of power or any multiple
testing issues. On the other hand, p-values are usually simpler to
compute, compared with a PPA that requires assumptions about
the distribution of effect sizes [3], and so we have reported both
here. We required that associations satisfy both p,1026 and
PPA.0.2 to be worthy of reporting in Table 2 (weaker suggestive
associations are reported in Table S1). A second advantage of a
Bayesian approach is that it has allowed us to give some weight to
non-additive genetic associations, while still giving an appropriate
weight to the more prevalent additive associations. Using p-values
it is not easy for the researcher to control the weight given to
different genetic models in an interpretable way. In fact, the
associations reported in Table 2 are all consistent with an additive
genetic model, and allowing for general associations had little
impact on our results. However we were able to allow for this
possibility without incurring a multiple testing penalty.
Materials and Methods
Ethics Statement
The London Life Sciences Population (LOLIPOP) study is
approved by the Ealing and St Mary’s Hospitals Research Ethics
Committees and written consent was obtained from all partici-
pants.
Participants
Participants were selected from the LOLIPOP study [6], an
ongoing collection of phenotypic data and blood samples on a
large number of Indian Asian and European white men and
women living in West London.
We had available a pool of 8371 men aged 35 to 75 years, for
whom all four grandparents were of Indian Asian descent born on
the Indian subcontinent. Recruitment and data collection are
described elsewhere [6]. The pool was split into two groups of sizes
4100 and 4271, from which 2706 and 2746 were selected for
genotyping in stages 1 and 2, respectively. In each stage the same
‘‘top and tail’’ selection procedure was used, based on four traits.
All T2D cases on treatment were selected, and other individuals
were selected on the basis of having a low glucose level
(,5.6 mmol/l), or in the top 500 or bottom 500 for one of waist
to hip ratio (WHR), diastolic blood pressure (DBP), or HDL-
cholesterol. Alcohol consumption was transformed to a factor with
3 categories: zero, ,=21 units/week, and.21 units/week. Based
on significance from multiple regression analysis, we made the
following adjustments prior to selection: for non-T2D cases,
glucose was adjusted for age and body mass index (BMI); DBP was
adjusted for age, BMI and alcohol; WHR was adjusted for age;
HDL was adjusted for BMI and alcohol. After adjustment, the
individuals with the top and bottom five measurements for each of
WHR, DBP and HDL were excluded, to avoid analysing extreme
outliers reflecting data anomalies. The top and bottom four
glucose measurements in non-T2D cases were also excluded. A
summary of the selection procedure is in Table S3. We evaluated a
quantitative metabolic syndrome phenotype with a continuous
score from 0–5 based on the International Diabetes Federation
(IDF) definition summarised in Text S1 [1]. We also considered a
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binary phenotype with scores 3–5 as cases and scores 0–2 as
controls. This did not reveal any new results and is therefore not
discussed here.
Genotyping
The Stage 1 samples were genotyped by DeCode, Iceland, using
the Illumina 300HumanHap Bead Chip, which includes 317,968
SNPs of which 308,942 are autosomal. Stage 2 samples were
genotyped using a custom array and Illumina Golden Gate
technology at Imperial College, Hammersmith Hospital. Due to a
problem with genotyping, a random set of 500 samples selected for
Stage 2 were not genotyped, and analyses proceeded without these
samples. This left a total of 2274 samples genotyped at 1370 SNPs.
A summary of the genotyping for both stages is in Tables S4 and
S5, and Text S2.
Statistical analysis
I. Quality control. Phenotypes and genotype data were
subjected to rigorous quality control procedures, detailed in Text
S2. In summary, individuals and SNPs were excluded based on
genotyping quality, Hardy-Weinberg equilibrium and relatedness.
In Stage 1, we investigated the effect of population structure
through principal component (PC) analysis. The first two PCs are
shown in Figure 2, and indicate a complex pattern of population
structure that has some correlation with religious affiliation
(Figure 2 top) and language (Figure 2 bottom). Among the first
fifteen PCs, only the first four were significantly associated with
any phenotype and these four were used to adjust for population
structure in the Stage 1 regression analyses. Computation of both
PCs and kinship coefficients used only every 10th SNP, in genome
order, to minimise any impact of LD. A summary of exclusions is
in Table S6.
II. Association analysis. In Stage 1, association of
individual SNP genotypes with each of the (adjusted) metabolic
traits and the metabolic syndrome phenotype were tested in
PLINK [23], using logistic regression for T2D and linear
regression for the other traits. For each SNP, both additive and
recessive genetic models were tested. To maximise power, each
individual was included in the analysis of each phenotype,
irrespective of the reason for selecting that individual. Perhaps
because of this and our adjustments, despite the top-and-tail
selection we found that standard regression p-values based on the
Gaussian statistical distribution showed correct type 1 error, as
evidenced by good adherence of observed quantiles to their
null expectations over all but the upper tail of the distribution
(Figure S1).
We selected 1536 SNPs for the Stage 2 Golden Gate custom
array, based on a number of conditions: 1433 were significant
under the additive model, either at p,1023 for one of the four
primary phenotypes, or at p,1025 for the two metabolic
syndrome phenotype, or at p,1025 under the recessive model
for any phenotype. An additional 103 SNPs were selected based
on being proxies (r2.0.9) for a top-ranked SNP, or for a SNP with
low design score, or based on candidate SNPs from the literature.
SNPs with p.1026 were excluded if they had high LD (r2.0.9)
with a genotyped SNP, or low design score. We tested association
of Stage 2 SNPs with each of the primary phenotypes and the
metabolic syndrome phenotype.
Data from both stages were pooled and association analysis was
carried out on the combined data, in the same way as for Stage 1,
including testing for recessive and dominant models, except that
PCs were not available to adjust for population structure. Bayes
factors (BFs) were calculated using both additive and general
models. For the quantitative traits, the additive model assumed a
linear trend in trait mean and constant trait variance with
increasing minor allele count (0,1, or 2), while the general model
allowed any changes in both mean and variance over genotypes.
For the binary traits (T2D and the two definitions of the metabolic
syndrome), the general model is described as BFr in the
supplementary material of [3]. Full R code for the quantitative
trait BFs is given in Text S3. We used the default prior parameters,
which imply that a 95% interval for the mean effect size is
approximately +/20.4 phenotype standard deviations, while
under the general model the phenotypic variance was allowed to
vary over genotypes by about 5%. The two Bayes factors were
combined using Bayes theorem to generate the PPA, giving a 4:1
weight in favour of the additive model, and a prior probability of
association of 1024 at each SNP. See Text S3 for the full R code
that includes all parameter values for all four Bayes factors.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0011961.s001 (0.01 MB
DOC)
Text S2
Found at: doi:10.1371/journal.pone.0011961.s002 (0.02 MB
DOC)
Figure 2. First and second principal components for stage 1 individuals colour coded by (a) religion and (b) language.
doi:10.1371/journal.pone.0011961.g002
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Text S3
Found at: doi:10.1371/journal.pone.0011961.s003 (0.02 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0011961.s004 (0.03 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0011961.s005 (0.01 MB
DOC)
Table S3 *Although individuals were selected based on the top
and bottom 500 ranked samples, some extra criteria were used in
the selection process as set out in the table. These criteria were
applied to the raw measurements, whereas selection of the ‘‘top’’
and ‘‘tail’’ was carried out on adjusted traits as described in the
methods section.
Found at: doi:10.1371/journal.pone.0011961.s006 (0.01 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0011961.s007 (0.01 MB
DOC)
Table S5 *In the combined analyses of stages 1 and 2, the
‘‘Total’’ numbers applied to the quantitative traits (HDL, WHR,
DBP and quantitative metabolic syndrome) and the Cases and
Controls numbers applied to T2D and binary metabolic
syndrome.
Found at: doi:10.1371/journal.pone.0011961.s008 (0.02 MB
DOC)
Table S6
Found at: doi:10.1371/journal.pone.0011961.s009 (0.01 MB
DOC)
Figure S1
Found at: doi:10.1371/journal.pone.0011961.s010 (0.08 MB TIF)
Acknowledgments
The authors would like to thank JS Kooner and J. Chambers for providing
data, and JS Kooner, J. Chambers, P Elliott and J Scott for contributing to
the design of the study.
Author Contributions
Analyzed the data: DZ. Wrote the paper: DZ DB. Contributed to the
design of the study: DZ DB.
References
1. Alberti KGMM, Zimmet P, Shaw J (2005) The metabolic syndrome – a new
worldwide definition. Lancet 366 (9491): 1059–1062.
2. Zabaneh D, Chambers JC, Elliott P, Scott J, Balding DJ, et al. (2009)
Heritability and genetic correlations of insulin resistance and component
phenotypes in Asian Indian families using a multivariate analysis. Diabetologia
52 (12): 2582–2589.
3. Stephens M, Balding DJ (2009) Bayesian statistical methods for genetic
association studies. Nature Reviews Genetics 10(681–690).
4. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al. (2007)
A common variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science 316 (5826): 889–894.
5. Yu W, Clyne M, Wulf A, Yesupriya A, Gwinn M, et al. (2009) Genopedia,
HuGE Navigator. Ref Type: Catalog.
6. Chambers JC, Elliott P, Zabaneh D, Zhang WH, Li Y, et al. (2008) Common
genetic variation near MC4R is associated with waist circumference and insulin
resistance. Nature Genetics 40 (6): 716–718.
7. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009)
Common variants at 30 loci contribute to polygenic dyslipidemia. Nature
Genetics 41 (1): 56–65.
8. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, et al. (2009)
Genome-wide association analysis of metabolic traits in a birth cohort from a
founder population. Nature Genetics 41 (1): 35–46.
9. Salonen JT, Uimari P, Aalto JM, Pirskanen M, Kaikkonen J, et al. (2007) Type 2
diabetes whole-genome association study in four populations: The DiaGen
consortium. American Journal of Human Genetics 81 (2): 338–345.
10. Saxena R, Voight BF, Lyssenko V, Burtt NP, deBakker PIW, et al. (2007)
Genome-wide association analysis identifies loci for type 2 diabetes and
triglyceride levels. Science 316 (5829): 1331–1336.
11. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genome-
wide association study of type 2 diabetes in Finns detects multiple susceptibility
variants. Science 316 (5829): 1341–1345.
12. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, et al. (2007) A genome-wide
association study identifies novel risk loci for type 2 diabetes. Nature 445 (7130):
881–885.
13. Steinthorsdottir V, thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T,
et al. (2007) A variant in CDKAL1 influences insulin response and risk of type 2
diabetes. Nature Genetics 39 (6): 770–775.
14. Timpson NJ, Lindgren CM, Weedon MN, Randall J, Ouwehand WH, et al.
(2009) Adiposity-Related Heterogeneity in Patterns of Type 2 Diabetes
Susceptibility Observed in Genome-Wide Association Data. Diabetes 58 (2):
505–510.
15. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-
analysis of genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nature Genetics 40(5): 638–645.
16. Lebrin F, Deckers M, Bertolino P, Ten Dijke P (2005) TGF-beta receptor
function in the endothelium. Cardiovasc Res 65: 599–608.
17. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, et al. (2009)
Genome-wide association study identifies eight loci associated with blood
pressure. Nature Genetics 41 (6): 666–676.
18. Benyamin, Sorensen TIA, Schousboe K, Fenger M, Visscher PM, et al. (2007)
Are there common genetic and environmental factors behind the endopheno-
types associated with the metabolic syndrome? Diabetologia 50 (9): 1880–1888.
19. Sjogren M, Lyssenko V, Jonsson A, Berglund G, Nilsson P, et al. (2008) The
search for putative unifying genetic factors for components of the metabolic
syndrome. Diabetologia 51 (12): 2242–2251.
20. Executive Summary of the third report of the national cholesterol education
program (NCEP) Expert Panel on Detection, evaluation and Treatment of
high blood cholesterol in Adults (Adult Treatment Panel III) 2001, JAMA 285:
2486–2497.
21. WHO: Definition, diagnosis, and classificatin of diaetes mellitus and its
complicatiohns. Report of a WHO Consultation, Available at http://www.
staff.ncl.ac.uk/philip.home/who_dmc.htm#MetabSyndDef. Accessed Feb
2009.
22. Joy T, Lahiry P, Pollex RL, Hegele RA (2008) Genetics of the metabolic
syndrome. Current Diabetes Reports 8: 141–148.
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, et al. (2007)
PLINK: A tool set for whole-genome association and population-based linkage
analyses. American Journal of Human Genetics 81 (3): 559–575.
24. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly
identified loci that influence lipid concentrations and risk of coronary artery
disease. Nature Genetics 40(2): 161–169.
25. Hiura Y, Shen CS, Kokubo Y, Okamura T, Morisaki T, et al. (2009)
Identification of genetic markers associated with high-density lipoprotein-
cholesterol by genome-wide screening in a Japanese population: the Suita study.
Circ J 73(6): 1119–1126.
26. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, et al. (2009) Loci
influencing lipid levels and coronary heart disease risk in 16 European
population cohorts. Nature Genetics 41(1): 47–55.
Metabolic Syndrome GWAS
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e11961
